Want to join the conversation?
$CVS said Repatha, evolocumab, from $AMGN will be added as only PCSK9 inhibitor for treating low-density lipoprotein cholesterol on the CVS/caremark commercial formularies. The decision comes after thorough evaluation of 2 new PCSK9 inhibitor therapies, which were approved by FDA earlier this year.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.